IFNA2 and nonpapillary renal cell carcinoma: Following the discovery that bevacizumab could be efficacious in ccRCC, two randomized phase III trials studied the combination of bevacizumab with IFN-α-2a [105] and IFN-α-2b [106], demonstrating PFS benefits but no OS benefit in first-line advanced-stage ccRCC.